-
3 Active Ingredients and Custom Manufacturing, Biologics and Formulations and Research-Led CDMO Stocks With a Strong Future Roadmap: Neuland Laboratories, Shilpa Medicare and Anthem Biosciences
- October 23, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
No Comments
Contract Manufacturing and API Innovator Stocks with a strong future roadmap: Neuland Laboratories, Shilpa Medicare and Anthem Biosciences. Compare price, valuation, return on equity and revenue growth as of 22 October 2026.
-
3 Oncology and Biologics, Formulation Outsourcing and Eye and Skin Care Brands Stocks With a Strong Future Roadmap: Shilpa Medicare, Innova Captab and Ajanta Pharma
- October 22, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Oncology and Contract Pharma Stocks with a strong future roadmap: Shilpa Medicare, Innova Captab and Ajanta Pharma. Compare price, valuation, return on equity and revenue growth as of 21 October 2026.
-
3 Oncology Generics, Branded Generics and Biologics Platform Stocks With a Strong Future Roadmap: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare
- October 21, 2026
- Posted by: Kunal Singla
- Category: Best Stocks
Specialty Generics and Oncology Stocks with a strong future roadmap: Natco Pharma, Emcure Pharmaceuticals and Shilpa Medicare. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
3 Sterile Injectables, Chronic Care Brands and Biologics Maker Stocks With a Strong Future Roadmap: Gland Pharma, Eris Lifesciences and Shilpa Medicare
- October 21, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Injectable and Specialty Pharma Stocks with a strong future roadmap: Gland Pharma, Eris Lifesciences and Shilpa Medicare. Compare price, valuation, return on equity and revenue growth as of 20 October 2026.
-
3 Biologics Maker, Specialty Ingredient and Pharmacy Retail Stocks With a Strong Future Roadmap: Shilpa Medicare, Viyash Scientific and Medplus Health Services
- October 14, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Shilpa Medicare, Viyash Scientific and Medplus Health Services compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.
-
3 Branded Formulation, Biologics and Pharma Service Stocks With a Strong Future Roadmap: Mankind Pharma, Shilpa Medicare and Indegene
- October 14, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Mankind Pharma, Shilpa Medicare and Indegene compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.
-
3 Fermentation Ingredient, Biologics and Global Generic Stocks With a Strong Future Roadmap: Concord Biotech, Shilpa Medicare and Aurobindo Pharma
- October 14, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Concord Biotech, Shilpa Medicare and Aurobindo Pharma compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.
-
Shilpa Medicare’s 238% Rally Now Faces a Real Earnings Test
- September 25, 2026
- Posted by: Chaitanya Auti
- Category: News
Shilpa Medicare’s 238% 2026 rally faces an earnings test after Q1FY27 revenue rose 43% and profit jumped 115%, partly aided by a one-time tax reversal.